MO33-2 Retrospective Analysis of Urothelial Carcinoma Treated with Enfortumab Vedotin at Our Institution

Enfortumab vedotin (EV) is an antibody-drug conjugate directed against Nectin-4, which is frequently expressed in urothelial carcinoma (UC). EV is approved in Japan based on the results of a phase III trial (EV-301) that confirmed its efficacy in patients with advanced UC who have previously received a platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. As EV has only been approved in Japan since September 2021 and there is insufficient experience with its use in real-world clinical practice, the efficacy and safety of EV in patients treated at our institution were reviewed.